Headlands Research, a clinical trial site network with locations across the U.S. and Canada, has made its first step into the ...

Following long-time chief José Almeida’s retirement earlier this year, Baxter announced it has officially named a new CEO. | ...

A phase 3 trial of Cogent Biosciences’ bezuclastinib has hit its primary endpoint, teeing the biotech up to seek FDA approval ...

To make matters worse, the biotech realized that the same duff drug product had been used in a separate ongoing study of ...

We’re in the midst of a paradigm shift in biomarker science. | The right biomarker signature can de-risk trials, guide ...

Apogee Therapeutics’ anti-IL-13 antibody has been tied to a 71% reduction in eczema severity after 16 weeks, hitting the main ...

Chugai, a Japanese company majority owned by Roche, has identified Gero’s platform as complementary to its own capabilities.